Vertex Secures FDA Approval for ALYFTREK A Game-Changer in Cystic Fibrosis Treatment

Published: 27 Dec 2024

Author: Precedence Research

Share :

Vertex Pharmaceuticals just announced that the FDA has approved ALYFTREK™, a once-daily triple-combination CFTR modulator for cystic fibrosis patients aged six years and older who have at least one copy of the F508del mutation or another CFTR mutation susceptible to treatment. This is Vertex's fifth FDA-approved CFTR modulator, and it further solidifies the company's already established position in this dreadful genetic disease. Clinical trials have demonstrated that ALYFTREK meets all essential non-inferiority endpoints against TRIKAFTA regarding lung function improvement and significant reductions in sweat chloride levels—a key biomarker of CFTR function. This means about 150 U.S. patients can receive treatment for one of the 31 previously untreated mutations. This shift in the landscape of CF care is set to occur due to the global approvals of this evolution and will provide hope and a better quality of life to thousands of patients across the globe.

Breaking New Ground in CF Treatment

AMYFTREK is administered as one convenient dose for maintaining adherence to CFTR modulation among CF patients. It was also launched for 150 U.S. patients who potentially have any one of the 31 previously untreated mutations that it targets. This therapy will now be available to patients with CF who are participating in an extensive Phase 3 trial encompassing more than a thousand participants across over 20 countries and more than 200 sites. Proven effective in its primary endpoint: noninferiority to TRIKAFTA in absolute changes in ppFEV1 and statistically significant improvements in sweat chloride levels (SwCl), a biomarker for CFTR function. ALYFTREK has demonstrated safety across different age groups in studies involving participants aged 6 years and older. The efficacy shown for this medication extends from ages 6 to 11. This larger footprint underlines Vertex's promise of enhanced therapeutic options available for CF patients and better outcomes for those they treat.

Expert Endorsements

Dr. Claire L. Keating, Co-Director of the Gunnar Esiason Adult Cystic Fibrosis and Lung Program, lauded the introduction of ALYFTREK, a medication for treating cystic fibrosis that is taken once daily. The changes promote improved methods for administering therapies for cystic fibrosis, which have long been time-consuming and challenging to transform, define eligibility, establish appealing accommodation standards, and demonstrate breakthrough efficacy in a highly transformational model of cystic fibrosis care. Vertex has now submitted ALYFTREK to regulatory agencies around the globe to create an aspirational model for future CF treatment worldwide that will have a broader impact on the CF patient population.

Vertex’s Vision for the Future

 According to Reshma Kewalramani, the Vertex CEO, for more than two decades, its north star has always been to address the cause of CF, treat more people with the disease, and improve CFTR functionality for more patients at normal levels. ALYFTREK—Vertex's once-daily doses of medication combined with mutation coverage and evidence of its proven treatment efficacy—have redefined the treatment of CF and illuminated the lives of thousands of CF patients.